Allan Shaw, maven of biotech finance markets and management, discusses the importance of cash management in the biotech industry, the difficulties faced by emerging biotech firms, the value of collaboration, and the need for innovation in biotech organizations.
Cash management is crucial for emerging biotechs during clinical trials, requiring smart spending and focus on key objectives.
Biotech leaders should refine their focus, prioritize resources, and make data-driven decisions to avoid wasteful spending and optimize resource allocation.
Deep dives
The Importance of Cash Management in the Biotech Industry
Cash management is a common challenge for emerging biotech companies, especially during the foray into clinical trials. The cost of doing business with other people's money is high, and spending can quickly outpace development time and regulatory requirements. It is essential for biotech leaders to prioritize cash management and resource allocation. This involves refining priorities, being smart about spending, and focusing on key objectives. Companies should establish budgets, create Gantt charts, and track actual results against budgets to ensure financial discipline. Additionally, maintaining a rolling forecast can provide a forward-looking view of cash burn and help inform financing strategies.
The Need for Business Acumen in Biotech Founders
Many biotech founders who come from scientific backgrounds lack business acumen, which can lead to wasteful spending. Cash management starts at the top, and biotech leaders need to refine their focus and prioritize their resources. Collaboration and a clear understanding of market opportunities, competitive differentiation, and value propositions are crucial for efficient resource allocation. It is important to ask critical questions, make data-driven decisions, and not let emotions or past success blind judgment. Additionally, understanding the true cost and time required for development can help companies create realistic cash burn forecasts.
Avoiding Unnecessary Spending in Early-Stage Biotechs
Early-stage biotechs often spend unnecessarily due to a lack of budgeting and financial discipline. To avoid this, companies should establish detailed and realistic cash burn forecasts early on. By maintaining a rolling forecast, regularly updating budgets, and aligning spending with milestones and development catalysts, companies can effectively manage their resources. It is important to hold Contract Research Organizations (CROs) accountable and actively manage the relationship to avoid excessive spending. Additionally, being mindful of differentiation, market opportunities, and the need for focused development can help optimize spending in early-stage biotechs.
Strategic Portfolio Management and Collaboration in Biotech
Strategic portfolio management and collaboration play vital roles in efficient resource allocation and cash management in biotech. Companies should consider prioritizing programs based on their value, development timelines, and the potential for meaningful differentiation. Managing the portfolio may involve reallocating resources, partnering with other companies to validate programs, and optimizing efficiencies in clinical trials through biomarkers and focused development approaches. Collaboration can also help gain access to additional expertise, resources, and funding opportunities. Biotech leaders should proactively challenge their organizational structure and encourage innovation in all aspects of their company to work smarter and navigate the competitive biotech landscape successfully.
It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. And, even when good data opens the cash floodgates, post-round cash management savvy isn't necessarily intuitive to academic and scientific founders. Cash runway preservation is, however, ingrained in the cerebral cortex of one of our favorite mavens of biotech finance markets and management, Mr. Allan Shaw. He joins us on this week’s episode of the Business of Biotech for a conversation on post-financing fundamentals for new and emerging biopharmas.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
